ESMO: Is Roche's new Tecentriq data a match for Keytruda's 'lead and loyalty' in lung cancer?

27th September 2019 Uncategorised 0

Right now, Merck’s Keytruda is the only immuno-oncology treatment approved solo in previously untreated non-small cell lung cancer. But Roche’s Tecentriq is looking to make it two. Friday, the Swiss drugmaker presented data showing Tecentriq could extend patients’ lives by an additional 7.1 months compared with chemo.

More: ESMO: Is Roche's new Tecentriq data a match for Keytruda's 'lead and loyalty' in lung cancer?
Source: fierce